Browse views: by Year, by Function, by GLF, by Subfunction, by Conference, by Journal

Polygenic in vivo validation of cancer mutations using transposons - art. no. 455

Chew, SK and Lu, D and Campos, LS and Scott, KL and Saci, A and Wang, J and Collinson, A and Raine, K and Hinton, J and Teague, JW and Jones, D and Menzies, A and Butler, AP and Gamble, J and O'Meara, S and McLaren, S and Chin, L and Liu, P and Futreal, PA (2014) Polygenic in vivo validation of cancer mutations using transposons - art. no. 455. Genome Biology. 455-.

Abstract

The in vivo validation of cancer mutations and genes identified in cancer genomics is resource-intensive because of the low throughput of animal experiments. We describe a mouse model that allows multiple cancer mutations to be validated in each animal line. Animal lines are generated with multiple candidate cancer mutations using transposons. The candidate cancer genes are tagged and randomly expressed in somatic cells, allowing easy identification of the cancer genes involved in the generated tumours. This system presents a useful, generalised and efficient means for animal validation of cancer genes

Item Type: Article
Additional Information: NIBR author: Saci, A institute: NIBR contributor address: Wellcome Trust Sanger Inst, Hinxton, England pl2@sanger.ac.uk; Baylor Coll Med, Houston, TX 77030 USA ; Novartis Inst Biomed Res, Cambridge, MA USA ; Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA ; Wellcome Trust Sanger Inst, Hinxton, England, Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA afutreal@mdanderson.org; Wellcome Trust Sanger Inst, Hinxton, England; Liu, P T; Wellcome Trust Sanger Inst, Hinxton, England
Date Deposited: 13 Oct 2015 13:11
Last Modified: 13 Oct 2015 13:11
URI: https://oak.novartis.com/id/eprint/24941

Search

Email Alerts

Register with OAK to receive email alerts for saved searches.